Concert Pharmaceuticals Names Høiland to its Board of Directors
30 April 2019 - - US-based Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) has appointed Jesper Høiland to its board of directors and will serve as a member of its compensation committee, effective immediately, the company said.

Høiland is an industry veteran with more than 30 years of experience in the biopharmaceutical industry across numerous senior leadership roles, geographies and therapeutic areas.

As president and chief executive officer of Radius Health, Inc., Høiland successfully launched Radius' first commercial product, Tymlos.

Prior to joining Radius, Høiland served as president and executive vice president of Novo Nordisk.

During his more than 20-year tenure at Novo Nordisk, Høiland held multiple global roles of increasing responsibility, including leading its International Operations which spanned 150 countries.

Høiland is a member of the board of directors of LEO Pharma and from 2014-2016 was a board member of PhRMA, the Pharmaceutical Research and Manufacturers of America. Høiland received his M.Sc. in Management from Copenhagen Business School in Denmark.

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs.

The company's approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy.

Concert's pipeline of innovative medicines targets autoimmune diseases and central nervous systems disorders.

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc. All other trademarks are those of their respective owners.